Efficacy of Digital Cognitive Behavioral Therapy for Insomnia (CBT-I) Utilizing Embodied Artificial Intelligence Agent in Virtual Reality

ConditionInsomnia
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorChinese University of Hong Kong

About this trial

The goal of this clinical trial is to evaluate whether a virtually embodied artificial intelligence (AI) agent delivered via VR-enhanced digital cognitive behavioral therapy for insomnia (dCBT-I) can improve insomnia outcomes and treatment adherence in adults with insomnia.

The main questions it aims to answer are:

\- Does VR-enhanced dCBT-I with an embodied AI agent lead to greater improvements in insomnia symptoms compared to app-based dCBT-I with an AI chatbot at post-intervention and 3-month follow-up?

Researchers will compare VR-enhanced dCBT-I with an embodied AI agent to app-based dCBT-I with an AI chatbot to see if the VR-enhanced intervention results in significantly improved clinical outcomes and adherence.

Participants will:

* Be randomly assigned to either the VR-enhanced AI agent intervention group or the app-based AI chatbot control group * Complete a digital cognitive behavioral therapy for insomnia (dCBT-I) program with either a virtually embodied AI agent (VR-based) or a chatbot-based application * Undergo assessments at baseline, post-intervention, and 3-month follow-up

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Adults of Chinese ethnicity, aged between 18 and 65 years.

Presence of insomnia, as indicated by a score of 10 or higher on the ISI.

Meeting the DSM-IV-TR diagnostic criteria for insomnia disorder. The 1-month duration criterion in DSM-IV-TR rather than the 3-month criterion in DSM-V is adopted to broaden the clinical relevance of the study findings.

Willing to provide online informed consent to participate in the study.

Disqualifiers

A current or history of any sleep disorders other than insomnia disorder, such as narcolepsy, obstructive sleep apnea, and restless legs syndrome.

A current or history of mental retardation or neuropsychiatric disorders other than depression or anxiety or stress disorders (as they are considered treatment outcomes), including bipolar disorder, schizophrenia, and substance use disorder.

Presence of serious suicidality, demonstrated by ideation with a plan or a previous suicide attempt.

Currently receiving long-term pharmacological treatment, including sleep-promoting agents.

Trial design

Design model

Parallel

Treatments tested in this trial

  • App-based dCBT-I with AI chatbot

    Behavioral

    Digital cognitive behavioral therapy for insomnia with two-way interactive, intelligent, and text-based conversational agents

  • VR-enhanced dCBT-I with embodied AI agent

    Behavioral

    Digital cognitive behavioral therapy for insomnia delivered in virtual reality with a two-way interactive, virtually embodied, and intelligent AI agent.

Treatment groups

168 Participants
are divided into 2 treatment groups
Group A: App-based dCBT-I with AI chatbotExperimental treatment 1 intervention
Group B: VR-enhanced dCBT-I with embodied AI agentActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Insomnia Severity Index

the severity of insomnia symptoms

Time frame
a) baseline; b) post-intervention (1-month after baseline); c) 3-month after intervention (4-month after baseline)
2

Insomnia Module in the Diagnostic Interview for Sleep Disorder (DISP)

the severity of insomnia symptoms

Time frame
a) baseline; b) post-intervention (1-month after baseline); c) 3-month after intervention (4-month after baseline)

Secondary outcomes

1

Sleep onset latency (SOL)

7-day sleep diary

Time frame
a) baseline; b) post-intervention (1-month after baseline); c) 3-month after intervention (4-month after baseline)
2

Wake after sleep onset (WASO)

7-day sleep diary

Time frame
a) baseline; b) post-intervention (1-month after baseline); c) 3-month after intervention (4-month after baseline)
3

Sleep efficiency (SE)

7-day sleep diary

Time frame
a) baseline; b) post-intervention (1-month after baseline); c) 3-month after intervention (4-month after baseline)
4

Total sleep time (TST)

7-day sleep diary

Time frame
a) baseline; b) post-intervention (1-month after baseline); c) 3-month after intervention (4-month after baseline)

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: